Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
PL
Wstęp: Trening mięśniowy to jeden z głównych elementów terapii zachowawczej poporodowych dysfunkcji mięśni dna miednicy (MDM). Celem badania było sprawdzenie, jaka część położnic potrafi wykonać prawidłową aktywację MDM oraz potwierdzenie zasadności wprowadzenia wczesnego instruktażu dotyczącego aktywacji tych struktur, już w trakcie pobytu w szpitalu. Materiał i metody: Analizie poddano 591 kart z fizjoterapeutycznego badania MDM wykonywanego na oddziale położnicznym. Do badania włączono karty pacjentek po porodach siłami natury, w wieku od 18 do 45 lat (średnio 31,03, SD 4,42). Na podstawie badania wykonywanego według schematu PERFECT oceniano umiejętność i jakość samodzielnej aktywacji MDM. Wyniki: Świadome napięcie MDM uzyskano u 68% badanych. Prawidłową, izolowaną aktywację MDM, w koordynacji z oddechem uzyskano u 54%. Wśród 13% badanych, oprócz świadomego napięcia MDM, zanotowano również aktywację innych mięśni. U 32% nie uzyskano początkowo świadomej aktywacji MDM: 25% uruchamiało inne grupy mięśniowe, 6% parło, u 1% nie zanotowano żadnej reakcji. Prawie 20% badanych zgłosiło, że nie wie czym są MDM. Wcześniejszy trening MDM zadeklarowało 55% badanych – 22,5% z nich nie wykonało świadomego napięcia MDM. Wnioski: Kobiety we wczesnym okresie połogu mają zbliżoną zdolność do samodzielnej aktywacji MDM co kobiety nie będące we wczesnym okresie poporodowym. Ze względu na częste błędy podczas samodzielnych prób uruchomienia mięśni dna miednicy potrzebny jest instruktaż dotyczący prawidłowej ich aktywacji.
EN
Introduction: One of the main elements in the conservative treatment of postpartum pelvic floor dysfunctions is muscle training. The aim of the study was to verify the ability to contract pelvic floor muscles (PFM) among Polish puerperae and to confirm the rationale to implement early instructions already during the hospital stay. Material and methods: Analysis included 591 reports from PFM physiotherapeutic examination carried out at maternity wards. The reports of patients aged 18 to 45 (mean 31.03, SD 4.42) after vaginal delivery were included in the study. Based on the examination conducted according to the PERFECT scheme, the ability to perform and the quality of PFM contraction were assessed. Results: Conscious PFM contraction was noted in 68% of the participants. Proper isolated PFM contraction coordinated with breathing was observed in 54% of the subjects. In 13% of the women, apart from conscious contraction of PFM, contraction of additional structures was also noted. In 32% of the participants, initial lack of conscious PFM contraction was noted. Among them, 25% contracted other muscle groups, 6% pushed, while for 1% of the subjects, no reaction was observed. Nearly 20% of the participants reported that they did not know what PFMs are. Previous PFM training was declared by 55% of the study participants, while 22.5% of them did not perform conscious PFM contraction. Conclusions: During early postpartum stage, women are able to activate the PFMs similarly to those not shortly after labour. Implementing instructions on how to contract pelvic floor muscles appropriately at the early postpartum phase is needed due to the existing large number of errors related to this action.
EN
Structural motifs found in naturally occurring compounds are frequently used by researchers to develop novel synthetic drug candidates. Some of these new agents are hybrid molecules which are designed through a concept of combining more than one functional element. In this report, anticancer activity of new synthetic molecular hybrids, substituted 3-diethoxyphosphorylnaphtho[2,3-b]furan-4,9-diones and 3-diethoxyphosphorylbenzo[f]indole-4,9-diones, which integrate natural 1,4-naphtalenedione scaffold, present in several anticancer agents, with pharmacophoric phosphonate moiety, were tested against hepatocellular cell line HepG2. Cytotoxicity was examined using MTT assay. Two most potent compounds, furandione 8a and benzoindoldione 12a, which reduced the number of viable HepG2 cells with the IC50 values of 4.13 µM and 5.9 µM, respectively, were selected for further research. These compounds decreased the mRNA expression levels of several genes: Bcl-2, angiogenic vascular endothelial growth factor (VEGF), c-Fos, caspase-8 and increased the expression of Bax, caspase-3 and -9, c-Jun, p21, p53, as determined by quantitative real-time PCR. The ability of these compounds to induce apoptosis and DNA damage was studied by flow cytometry. The obtained data showed that the new compounds inhibited cell viability by increasing apoptosis and decreasing angiogenesis. Compound 8a was a much stronger apoptosis inducer as compared with 12a and strongly activated the intrinsic pathway of apoptosis, associated with the loss of mitochondrial membrane potential and changes in Bax/Bcl-2 ratio. These findings show that the synthetic hybrids combining 1,4-naphthalenedione system and phosphonic acid moiety display potential to be further explored in the development of new anticancer agents.
EN
Natural polyphenols and polyphenol-rich extracts have been found to possess preventive and therapeutic potential against several types of cancers, including colorectal cancer (CRC), which is an example of an inflammation-associated cancer. This study examines the chemopreventive effect of a Japanese quince (Chaenomeles japonica) fruit flavanol preparation (JQFFP) on colon cancer SW-480 cells. JQFFP, rich in procyanidin monomers and oligomers, was found to inhibit the SW-480 cell viability by 40% at 150 µM catechin equivalents (CE) after 72 h incubation when compared to control, but it was non-toxic to normal colon fibroblast CCD-18Co cells. Furthermore, 100 µM CE JQFFP suppressed COX-2 mRNA expression to 36.7% of control values and protein expression to 77%. In addition, JQFFP reduced the MMP-9 protein expression (to 24% vs. control at 100 µM CE) and caused inhibition of its enzymatic activity (to 35% vs. control at 100 µM CE). Not only did JQFFP inhibit the COX-2 and MMP-9 levels, but it also reduced the NF-κB protein expression (to 65% of control) and phosphorylation of its p65 subunit (to 51%) at 100 µM CE. These results provide the first evidence that JQFFP inhibits COX-2, MMP-9, and NF-κB expression, suggesting that it has cytotoxic, anti-inflammatory, and anti-metastatic activities towards the colon cancer SW-480 cells.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.